Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
XBI vs XOVR: how they differ
XBI and XOVR hold 0% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR(R) S&P(R) Biotech ETF and ERShares Private-Public Crossover ETF.
What they hold in common
By the books each fund has filed, XBI and XOVR hold 0% of their money in the same securities at the same weight.
| Only in XBI | Only in XOVR |
|---|---|
| MODERNA INC 2.87% | Nvidia Corp 9.48% |
| TWIST BIOSCIENCE CORP 1.81% | Astera Labs Inc 7.75% |
| HALOZYME THERAPEUTICS INC 1.47% | Alphabet Inc 6.53% |
| NATERA INC 1.46% | Meta Platforms Inc 4.47% |
| KYMERA THERAPEUTICS INC 1.45% | Applovin Corp 3.95% |
| TRAVERE THERAPEUTICS INC 1.40% | Natera Inc 3.70% |
| ROIVANT SCIENCES LTD 1.39% | Robinhood Markets Inc 3.56% |
| ORUKA THERAPEUTICS INC 1.38% | Veeva Systems Inc 3.17% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 10, 2026.
| XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | XOVR ERShares Private-Public Crossover ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | ERShares |
| What it is | SPDR S&P Biotech | Private-Public Crossover |
| Total return, 1 year | +64.0% | 0.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +46.5 pts | −17.5 pts |
| Expense ratio | 0.35% | 0.75% |
| Already in the S&P 500 | 8.5% | 43.4% |
| Holdings | 154 | 32 |
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
XOVR in plain words
XOVR is an index equity fund tracking the Private-Public Crossover. Over the year to Sep 11, 2026 it returned 0.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.75% a year. By its holdings filed for Jun 30, 2026, 43% of the fund by weight is stocks the S&P 500 also holds, across 32 positions, with the top ten at 63.1%. It sat 4.2% below its high of Oct 27, 2025 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, XBI or XOVR?
- In the year to Sep 13, 2026, with distributions reinvested, XBI returned +64.0% and XOVR returned 0.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, XBI or XOVR?
- XBI charges 0.35% a year and XOVR charges 0.75%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do XBI and XOVR overlap with the S&P 500?
- By their latest filed holdings, 8% of XBI and 43% of XOVR by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, XBI against XOVR, data as of Sep 13, 2026. https://etfiq.com/compare/any/xbi-vs-xovr Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources